IPO Year: 2016
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/4/2025 | $12.00 | Buy | H.C. Wainwright |
| 12/30/2024 | $12.00 | Buy | H.C. Wainwright |
8-K - MetaVia Inc. (0001638287) (Filer)
S-1 - MetaVia Inc. (0001638287) (Filer)
8-K - MetaVia Inc. (0001638287) (Filer)
8-K - MetaVia Inc. (0001638287) (Filer)
8-K - MetaVia Inc. (0001638287) (Filer)
8-K - MetaVia Inc. (0001638287) (Filer)
8-K - MetaVia Inc. (0001638287) (Filer)
424B5 - MetaVia Inc. (0001638287) (Filer)
8-K - MetaVia Inc. (0001638287) (Filer)
10-Q - MetaVia Inc. (0001638287) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00
H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
Fastest customizable press release news feed in the world
Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54 Significant Direct Hepatic Activity with a 23.7% Reduction in Liver Stiffness (VCTE) by Day 54 Strong Glycemic Response with a 12.3 mg/dL Fasted Glucose Reduction by Day 54 Robust Weight Loss with 9.1% Reduction (21.2 lbs) by Day 54 CAMBRIDGE, Mass., Jan. 5, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive statistically significant results from the 8-week (extended from four weeks) non-titrated 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual ox
CAMBRIDGE, Mass., Dec. 29, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference. Members of MetaVia's business development and clinical teams will attend the conference, which will take place January 8-10 at the Chateaux Deer Valley in Park City, Utah. About MetaViaMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently devel
CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that on December 19, 2025, it received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result, the listing matter has been closed. About Met
CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA) ("MetaVia" or the "Company"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a 1-for-11 reverse stock split of its common stock, par value $0.001 ("common stock"), effective at 5:00 p.m. Eastern Time on December 4, 2025. Beginning on December 5, 2025, the common stock will trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis. At the Company's annual meeting of stockholders on June 30, 2025, the stockholders approved a proposal
Oral GPR119 Agonist Demonstrated Clinically Meaningful Reductions in HbA1c, Improvements in Liver Inflammation and Fibrosis, and Favorable Changes in Plasma Lipidomic Profiles CAMBRIDGE, Mass., Nov. 7, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of positive new data from its Phase 2a clinical trial evaluating vanoglipel (DA-1241), a potent and selective G protein-coupled receptor 119 (GPR119) agonist, as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH). The data highlight vanoglipel's differentiated dual activity across both hepatic a
Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Non-Titrated Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected by Year-End 2025 $14.3 Million in Cash at End of Third Quarter is Expected to Fund the Company Into 2026 CAMBRIDGE, Mass., Nov. 6, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate strategic update.
New Phase 1 PK Data Support Once-Weekly Dosing; Clinically Meaningful Weight Loss Observed Without Dose Titration DA-1726 Achieves Superior Lipid-Lowering Effects and Comparable Weight Loss to Pemvidutide in Pre-clinical Models CAMBRIDGE, Mass., Nov. 4, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), in two poster presentations at ObesityWeek® 2025, taking place in-person and virtuall
CAMBRIDGE, Mass., Oct. 27, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data on Vanoglipel (DA-1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, has been accepted for a poster presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2025, taking place November 7-11, 2025 in Washington, D.C. Title: Vanoglipel (DA-1241), a GPR119 Agonist, Demonstrates Hepatoprotective Effects Through Improvi
CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that two abstracts highlighting data on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), have been accepted for poster presentations at ObesityWeek® 2025, taking place in-person and virtually November 4-7, 2025 in Atlanta, GA. Title: Safety, Tolerability, and Pharmacokinetics of DA-1726, an Oxyntomodu
CAMBRIDGE, Mass., Oct. 14, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that President and Chief Executive Officer, Hyung Heon Kim, will present a company overview at the H.C. Wainwright Liver Disease Virtual Conference taking place October 21-22, 2025. Mr. Kim and Marshall H. Woodworth, Chief Financial Officer, will also participate in one-on-one meetings. Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting